Twelve Years of Experience of Acquired Hemophilia A: Trials and Tribulations in South Australia

 

 Buy Article Permissions and Reprints

ABSTRACT

Acquired hemophilia A (AH) is a rare and serious acquired bleeding disorder where prompt and correct diagnosis is crucial, and immune suppression is often required for factor VIII (FVIII) autoantibody eradication. The acquired FVIII deficiency usually manifests as bruises and bleeding, and treatment such as FVIII has limited efficacy because of the neutralizing FVIII inhibitor. Expensive bypassing agents such as recombinant activated factor VII (rFVIIa) may be required to treat clinically significant bleeding. This report summarizes the experience related to AH from a large Australian hemophilia center based in South Australia. We identified 25 patients retrospectively over 12 years (1997 to 2008) and reviewed diagnostic features, treatment for bleeds and to eradicate the autoantibody, treatment response, and survival outcomes. The incidence in South Australia was 1.20 cases per million/year with a median age of 78 years with an approximately equivalent sex ratio (12 males versus 13 females); median FVIII and inhibitor titer were 2.5 IU/dL and 11.0 BU/mL, respectively. Twenty-four patients were evaluated further. Thirteen patients (54%) required hemostatic agents, and rFVIIa was used in seven for major bleeds, of which four were limb or life threatening. Eighteen patients were treated by hematologists with immune suppression, and combination steroid and azathioprine was used most commonly to eradicate autoantibody; 15 of these 18 achieved remission (i.e., 83% response rate). Two patients had persistent low-titer inhibitor when treatments were withdrawn, and one died of a fatal bleed shortly after starting treatment. One had spontaneous remission. Five patients (33%) relapsed, three in less than 6 months after starting treatment; all were retreated successfully. Rituximab was used in six patients for high-titer inhibitor, second relapse, two life-threatening bleeds, underlying lymphoma, and steroid intolerance, respectively. Overall mortality was 25% (n = 6), five of whom were not treated. Advanced age and lack of treatment were predictive of poor survival outcomes. The very elderly (>75 years of age) may warrant a different treatment modality such as rituximab, which is potentially more tolerable and efficacious.

REFERENCES

• 1 Collins P, Macartney N, Davies R et al.. A population based, unselected, consecutive cohort of patients with acquired hemophilia A.  Br J Haematol. 2004;  124(1) 86-90
  CrossrefPubMedGoogle Scholar
• 2 Collins P W, Hirsch S, Baglin T P et al.. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.  Blood. 2007;  109(5) 1870-1877
  CrossrefPubMedGoogle Scholar
• 3 Collins P W. Treatment of acquired hemophilia A.  J Thromb Haemost. 2007;  5(5) 893-900
  CrossrefPubMedGoogle Scholar
• 4 Franchini M, Lippi G. Acquired factor VIII inhibitors.  Blood. 2008;  112(2) 250-255
  CrossrefPubMedGoogle Scholar
• 5 Delgado J, Jimenez-Yuste V, Hermandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.  Br J Haematol. 2003;  121 21-35
  CrossrefPubMedGoogle Scholar
• 6 Hay C R, Negrier C, Ludlam C A. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicenter study.  Thromb Haemost. 1997;  78 1463-1467
  PubMedGoogle Scholar
• 7 Hay C, Brown S, Collins P et al.. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors' Organisation.  Br J Haematol. 2006;  133 591-605
  CrossrefPubMedGoogle Scholar
• 8 Yee T T, Taher A, Pasi K J, Lee C A. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period.  Clin Lab Haematol. 2000;  22(5) 275-278
  CrossrefPubMedGoogle Scholar
• 9 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII.  Thromb Haemost. 1981;  45(3) 200-203
  PubMedGoogle Scholar
• 10 Burnet S P, Duncan E M, Lloyd J V, Han P. Acquired haemophilia in South Australia: a case series.  Intern Med J. 2001;  31(9) 556-559
  CrossrefPubMedGoogle Scholar
• 11 Garvey B. Rituximab in the treatment of autoimmune haematological disorders.  Br J Haematol. 2008;  141 149-169
  CrossrefPubMedGoogle Scholar
• 12 Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.  Blood. 2004;  103(12) 4424-4428
  CrossrefPubMedGoogle Scholar
• 13 Abdallah A, Coghlan D W, Duncan E M, Chunilal S D, Lloyd J V. Rituximab-induced long-term remission in patients with refractory acquired hemophilia.  J Thromb Haemost. 2005;  3(11) 2589-2590
  CrossrefPubMedGoogle Scholar
• 14 Aggarwal A, Grewal R, Green R J et al.. Rituximab for autoimmune haemophilia: a proposed treatment algorithm.  Haemophilia. 2005;  11(1) 13-19
  CrossrefPubMedGoogle Scholar
• 15 Lloyd J V, Street A M, Berry E et al.. Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand.  Aust N Z J Med. 1997;  27(6) 658-664
  PubMedGoogle Scholar
• 16 Lian E C, Villar M J, Noy L I, Ruiz-Dayao Z. Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone.  Am J Hematol. 2002;  69 294-295
  CrossrefPubMedGoogle Scholar

Lay TayM.B. B.S. F.R.C.P.A. 

Division of Haematology, SA Pathology, South Australia, Australia

PO Box 14, Rundle Mall, Adelaide SA 5000, Australia

Email: lay.tay@imvs.sa.gov.au